ProCE Banner Activity

Phase II Study: Pembrolizumab Plus Pomalidomide and Dexamethasone Active in R/R Multiple Myeloma

Slideset Download
Conference Coverage
Combination treatment with pembrolizumab plus pomalidomide/dexamethasone showed an ORR of 65% in relapsed/refractory MM.

Released: December 08, 2016

Expiration: December 07, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen